<DOC>
	<DOC>NCT00422994</DOC>
	<brief_summary>This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.</brief_summary>
	<brief_title>A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion: Patients and subjects between 1879 years old. End stage renal patients who are consistently receiving dialysis for a minimum of 3.5 hours, three times per week, with hemodialysis blood flow rates of &gt;200mL/min may be eligible to enter the study. Patients must also have systolic blood pressure 100190mmHg and diastolic blood pressure &lt;120mmHg. Healthy subjects must have systolic blood pressure 100150mmHg. Exclusion: Female subjects who are pregnant and/or breastfeeding must not participate in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>end stage renal impairment</keyword>
	<keyword>tolerability</keyword>
	<keyword>ropinirole</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hemodialysis</keyword>
</DOC>